Holen Sie sich die Stockscreener-App
5.325
13.41%
-0.825
Handel nachbörslich:
5.43
0.105
+1.97%
Pepgen Inc Aktie (PEPG) Neueste Nachrichten
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Aug Volume: Is PepGen Inc stock a smart retirement pickPrice Action & Technical Pattern Recognition Alerts - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
PepGen CEO McArthur sells $32875 in shares By Investing.com - Investing.com Nigeria
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com Nigeria
How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN
PepGen unveils new research at MDA2026 poster session - Traders Union
Research Analysts Offer Predictions for PepGen Q1 Earnings - MarketBeat
Profit Review: Can PepGen Inc. stock double in the next year2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Momentum: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEARTrade Entry Summary & Short-Term Trading Alerts - baoquankhu1.vn
PepGen CEO McArthur sells $32875 in shares - Investing.com
Surprises Report: How does PepGen Inc correlate with NasdaqJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - wjfw.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
PepGen Still On Track For PGN-EDODM1 Readouts Despite FDA Partial Hold - Citeline News & Insights
PepGen: Stock Slides On FDA Study HoldI'm Firmly On The Sidelines (NASDAQ:PEPG) - Seeking Alpha
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - BioPharma Dive
Stifel reiterates Buy on PepGen stock amid partial clinical hold By Investing.com - Investing.com India
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com Nigeria
PepGen: Clinical and Safety Uncertainties, FDA Partial Hold, and Valuation Gap Support Underperform Rating - TipRanks
Grocery Outlet Posts Downbeat Q4 Earnings, Joins SES AI, PepGen And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
PepGen stock slides on FDA partial hold (PEPG:NASDAQ) - Seeking Alpha
PepGen Updates EDO Platform and DM1 Program Outlook - TipRanks
PepGen falls 20% despite earnings beat on FDA hold concerns - Investing.com South Africa
Why Is PepGen Stock Falling Thursday?PepGen (NASDAQ:PEPG) - Benzinga
FDA places partial clinical hold on PepGen’s DM1 trial By Investing.com - Investing.com Canada
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - PharmiWeb.com
PepGen Announces Regulatory Updates on FREEDOM2 - pharmiweb.com
Stocks to Watch : Broadcom, StubHub, PepGen, Veeva Systems - marketscreener.com
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com South Africa
PepGen reports Q4 EPS (27c), consensus (39c) - TipRanks
PepGen announce FDA placed partial clinical hold on Phase 2 trial of PGN-EDODM1 - TipRanks
PepGen's Phase 2 Trial of Drug to Treat Multisystem Disorder Placed on Hold by US FDA - marketscreener.com
US FDA puts partial clinical hold on PepGen's muscle disease drug trial - AOL.com
Biotech firm PepGen's Q4 net loss narrows - TradingView
PepGen Faces FDA Partial Hold Amid Ongoing FREEDOM2 Trial - TipRanks
PepGen stock plunges 26% on FDA partial clinical hold By Investing.com - Investing.com Canada
PepGen (NASDAQ:PEPG) Issues Quarterly Earnings Results, Beats Expectations By $0.13 EPS - MarketBeat
PepGen IncU.S. FDA places Freedom2 trial on partial clinical hold related to preclinical pharmacology and toxicology - marketscreener.com
Pepgen IncU.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology - TradingView
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PepGen Inc. has received regulatory approval to launch its Freedom2 clinical trial program in South Korea, Australia, and New Zealand. - Bitget
FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial - Bitget
PEPG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
US FDA puts partial clinical hold on PepGen’s muscle disease drug trial - WTAQ
PepGen to Participate in the Leerink Global Healthcare Conference - PharmiWeb.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):